Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb 15;11(4):695-705.
doi: 10.4161/cc.11.4.19120.

Transient overexpression of cyclin D2/CDK4/GLP1 genes induces proliferation and differentiation of adult pancreatic progenitors and mediates islet regeneration

Affiliations

Transient overexpression of cyclin D2/CDK4/GLP1 genes induces proliferation and differentiation of adult pancreatic progenitors and mediates islet regeneration

Shuyuan Chen et al. Cell Cycle. .

Abstract

The molecular mechanism of β-cell regeneration remains poorly understood. Cyclin D2/CDK4 expresses in normal β cells and maintains adult β-cell growth. We hypothesized that gene therapy with cyclin D2/CDK4/GLP-1 plasmids targeted to the pancreas of STZ-treated rats by ultrasound-targeted microbubble destruction (UTMD) would force cell cycle re-entry of residual G(0)-phase islet cells into G(1)/S phase to regenerate β cells. A single UTMD treatment induced β-cell regeneration with reversal of diabetes for 6 mo without evidence of toxicity. We observed that this β-cell regeneration was not mediated by self-replication of pre-existing β cells. Instead, cyclin D2/CDK4/GLP-1 initiated robust proliferation of adult pancreatic progenitor cells that exist within islets and terminally differentiate to mature islets with β cells and α cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Triple staining for pancreas tissue at magnification of 200x. Anti-insulin (green), Anti-glucagon (red), and anti-nuclear (blue) antibodies were used. Upper left: normal pancreatic islet; Upper middle: STZ treated; Upper right: STZ plus RIP-DsRed; Middle left: RIP-cyclin D2 treated; Middle center: RIP-CDK4 treated; Middle right: RIP-GLP1 treated; Lower left: RIP-cyclin D2/CDK4 treated; Lower center: RIP-cyclin D2/CDK4/GLP1 treated; Lower right: H&E staining for similar slide of RIP-cyclin D2/CDK4/GLP1. Figure at the bottom is the β cell fraction, *p < 0.05; **p < 0.001 vs. STZ control; n = 6 animals, Error bars represent mean ± SEM, N values are numbers of pancreas analyzed for each group, all animals killed at 4 weeks after UTMD.
Figure 2
Figure 2
(A) Plot of fasting blood glucose level; (B) Plot of fasting blood c-peptide level; (C) plot of fasting blood insulin level; (D) glucose tolerance test curve; (E) plot of fasting blood glucose level of time-course experiment; (F) plot of fasting blood insulin level of time-course experiment; (G) plot of fasting blood c-peptide level of time-course experiment; H: rats body weight changes during time-course experiment; *p < 0.05; **p < 0.001 vs. STZ control; n = 6 animals, Error bars represent mean ± SEM, N values are numbers of pancreas analyzed for each group. The glucose tolerance test was performed at 4 weeks after UTMD.
Figure 3
Figure 3
Pancreatic transgene expression at one week after cyclin D2/CDK4/GLP-1 gene delivery by UTMD (animals killed at one week after UTMD). Cyclin D2 and CDK4 signal is seen in the cytoplasm and nucleus of insulin- and glucagon-positive cells only; GLP-1 signal seen in the cytoplasm of insulin- and glucagon-positive cells. x400 magnification.
Figure 4
Figure 4
Transient transgenic expression of human cyclin D2 in rat pancreas. Upper left: rat pancreas of RIP-cyclin D2/CDK4/GLP1 treated group one week after UTMD; Upper right: two weeks after UTMD; Lower left: 4 weeks after UTMD; Lower right: 12 weeks after UTMD; x200 magnification.
Figure 5
Figure 5
Immunofluorescent images one week after UTMD with GLP-1/cyclin D2/CDK4 (animals euthanized one week after UTMD), showing co-expression of insulin and amylase (upper left), insulin and glucagon (upper right), glucagon and amylase (lower left), and insulin, amylase and glucagon (lower right). The coexpression of insulin, glucagon and amylase indicates pluripotent pancreatic progenitors within an adult pancreatic islet. x200 magnification. Bottom panel is a plot of percentage of co-expression of insulin, glucagon and amylase in total β cells for the different experimental groups. *p < 0.05 vs. Normal group and STZ group; **p < 0.0001 vs. normal and STZ groups. n = 6 animals, Error bars represent mean ± SEM, N values are numbers of pancreas analyzed for each group.
Figure 6
Figure 6
Top panel: Ki-67 staining shown in the nucleus of insulin and glucagon positive cells in the pancreas of diabetic rat one week after UTMD with cyclin D2/CDK4/GLP1 (animals euthanized one week after UTMD), x600 magnification; the graph is a plot of the percentage of Ki-67 positive cells in total β cells for all experimental groups. #p > 0.05 vs. Normal group and STZ group; **p < 0.0001 vs. normal and STZ groups. n = 6 animals, Error bars represent mean ± SEM, N values are numbers of pancreas analyzed for each group. Third panel: Insulin and glucagon positive cells are self-duplicating in the pancreas of diabetic rat one week after UTMD with cyclin D2/CDK4/GLP-1 genes (animals euthanized one week after UTMD). Histone H3 (phospho-Ser10) (a mitosis marker) is clearly seen in the nucleus of insulin and glucagon positive cells, x600 magnification. Bottom panel is a plot of the percentage of Histone H3 positive cells in total β cells for all experimental groups. #p > 0.05 vs. Normal group and STZ group; **p < 0.0001 vs. normal and STZ groups. n = 6 animals, Error bars represent mean ± SEM, N values are numbers of pancreas analyzed for each group.
Figure 7
Figure 7
Islet transcriptional factors seen in the nucleus of insulin and glucagon positive cells in the pancreas of diabetic rat one week after UTMD with cyclin D2/CDK4/GLP1 (animals euthanized one week after UTMD). x600 magnification.

Similar articles

Cited by

References

    1. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the US. Diabetes Care. 2009;32:2225–2229. doi: 10.2337/dc090459. - DOI - PMC - PubMed
    1. Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of β cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab. 2007;3:758–768. doi: 10.1038/ncpendmet0647. - DOI - PubMed
    1. Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia. 2008;51:703–713. doi: 10.1007/s00125-008-0936-9. - DOI - PubMed
    1. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia. 2005;48:2221–2228. doi: 10.1007/s00125-005-1949-2. - DOI - PubMed
    1. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102–110. doi: 10.2337/diabetes.52.1.102. - DOI - PubMed

Publication types

MeSH terms